Latest Ratios: P/E Ratio -2.8x · EV/EBITDA N/A · ROE -79.0%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $103M | $92M | $64M | $80M | $59M | $510M | — | — |
| Enterprise Value | $68M | $57M | $26M | $5M | $-59065680 | $321M | — | — |
| P/E Ratio → | -2.84 | — | — | — | — | — | — | — |
| P/S Ratio | 7.58 | 6.80 | 4.94 | 7.24 | 8.68 | 340.85 | — | — |
| P/B Ratio | 2.80 | 2.25 | 1.30 | 0.95 | 0.48 | 2.74 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.24 | 2.04 | 0.44 | -8.67 | 214.85 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.8% | 49.8% | 45.7% | 43.1% | 13.3% | -78.0% | -162.2% | — |
| Operating Margin | -273.4% | -273.4% | -335.3% | -436.1% | -1084.2% | -4336.1% | -7990.1% | — |
| Net Profit Margin | -262.3% | -262.3% | -315.9% | -401.0% | -1073.7% | -4333.8% | -7944.6% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -79.0% | -79.0% | -61.0% | -42.5% | -47.2% | -51.2% | -48.7% | -65.3% |
| ROA | -62.3% | -62.3% | -53.2% | -38.8% | -43.5% | -47.3% | -45.8% | -61.4% |
| ROIC | -310.8% | -310.8% | -307.8% | -485.0% | -3454.2% | -3950.5% | -498.0% | — |
| ROCE | -79.2% | -79.2% | -63.8% | -45.7% | -47.4% | -51.0% | -48.8% | -69.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.00 | — | — | 0.00 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.85 | -0.76 | -0.89 | -0.96 | -1.01 | -0.93 | -0.92 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — |
Net cash position: cash ($35M) exceeds total debt ($314000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.34 | 4.34 | 6.15 | 10.14 | 14.62 | 12.55 | 16.60 | 15.63 |
| Quick Ratio | 3.73 | 3.73 | 5.48 | 9.39 | 14.09 | 12.28 | 16.18 | 15.63 |
| Cash Ratio | 2.99 | 2.99 | 4.31 | 8.57 | 13.43 | 11.98 | 15.23 | 14.78 |
| Asset Turnover | — | 0.25 | 0.22 | 0.12 | 0.05 | 0.01 | 0.00 | — |
| Inventory Turnover | 0.96 | 0.96 | 1.20 | 0.95 | 1.28 | 0.62 | 0.45 | — |
| Days Sales Outstanding | — | 175.52 | 235.17 | 136.68 | 167.66 | 157.13 | 216.02 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $94M | $72M | $71M | $70M | $70M | $25M | $5M |
Liquidity and capital exhaustion
According to recent market data, Hyperfine trades at a price-to-sales multiple of 9.13, a valuation that appears disconnected from the company's modest 5.22% year-over-year revenue growth and persistent inability to demonstrate a clear, near-term path toward positive earnings per share.
The current P/S multiple suggests that investors are pricing in a high-growth trajectory that the company's recent performance fails to support. This valuation premium warrants caution, as it implies significant future market share gains that may be difficult to achieve given the current institutional sales cycle.
As reported in financial statements, Hyperfine's ROIC has remained deeply negative, hovering near -99.7% in the most recent quarter, which indicates that the company is currently destroying shareholder value rather than compounding capital through its investment in portable imaging technology.
The persistent negative return on invested capital reflects the high cost of maintaining a specialized sales force and R&D infrastructure relative to the current revenue base. Investors should monitor whether future product iterations can improve unit economics enough to reverse this trend of capital decay.
Based on the provided figures, the cash conversion cycle has remained excessively long, peaking at 648 days in 2024Q4, which suggests that Hyperfine faces significant structural challenges in converting its inventory of Swoop systems into cash within a reasonable timeframe.
The extended days sales outstanding and high inventory levels indicate that the company's working capital management is currently a drag on its limited cash reserves. This inefficiency appears to be a byproduct of the complex, long-lead-time procurement processes inherent in hospital capital equipment sales.
As indicated by the latest quarterly filings, the current ratio has compressed from 10.14 in 2023Q4 to 5.52 in 2026Q1, signaling that the company's liquidity buffer is shrinking as it continues to fund its operations through its existing cash reserves.
While the current ratio remains numerically high, the rapid decline suggests that the company's cash burn is outpacing its ability to generate internal liquidity. This trend warrants further investigation into the company's potential need for dilutive financing to sustain operations over the next twelve months.
The price-to-book ratio of 3.38 is frequently misapplied to Hyperfine, as it obscures the reality that the company's book value is heavily comprised of intangible assets and R&D-heavy equipment that may hold little liquidation value in a distressed scenario.
Investors should instead focus on the cash burn rate and the total addressable market penetration, as the book value provides a false sense of security for a company that is fundamentally a technology-driven R&D platform. Relying on P/B ignores the high probability that the company's assets are not easily monetizable.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HYPR stock.
Hyperfine, Inc.'s current P/E ratio is -2.8x. This places it at the 50th percentile of its historical range.
Hyperfine, Inc.'s return on equity (ROE) is -79.0%. The historical average is -56.4%.
Based on historical data, Hyperfine, Inc. is trading at a P/E of -2.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Hyperfine, Inc. has 49.8% gross margin and -273.4% operating margin.